Characterization of an adaptive immune response in microsatellite-instable colorectal cancer

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646 - 74; http://dx.doi.org/10.1016/j.cell.2011.02.013; PMID: 21376230
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298 - 306; http://dx.doi.org/10.1038/nrc3245; PMID: 22419253
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, Camus M, Gillard M, Bruneval P, Fridman WH, et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 2010; 138:1429 - 40; http://dx.doi.org/10.1053/j.gastro.2009.10.057; PMID: 19909745
   PubMed Web of Science ®Google Scholar
• Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353:2654 - 66; http://dx.doi.org/10.1056/NEJMoa051424; PMID: 16371631
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960 - 4; http://dx.doi.org/10.1126/science.1129139; PMID: 17008531
   PubMed Web of Science ®Google Scholar
• Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50:113 - 30; http://dx.doi.org/10.1111/j.1365-2559.2006.02549.x; PMID: 17204026
   PubMed Web of Science ®Google Scholar
• Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn 2008; 10:13 - 27; http://dx.doi.org/10.2353/jmoldx.2008.070082; PMID: 18165277
   PubMed Web of Science ®Google Scholar
• Duval A, Rolland S, Compoint A, Tubacher E, Iacopetta B, Thomas G, Hamelin R. Evolution of instability at coding and non-coding repeat sequences in human MSI-H colorectal cancers. Hum Mol Genet 2001; 10:513 - 8; http://dx.doi.org/10.1093/hmg/10.5.513; PMID: 11181575
   PubMed Web of Science ®Google Scholar
• Dolcetti R, Viel A, Doglioni C, Russo A, Guidoboni M, Capozzi E, Vecchiato N, Macrì E, Fornasarig M, Boiocchi M. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol 1999; 154:1805 - 13; http://dx.doi.org/10.1016/S0002-9440(10)65436-3; PMID: 10362805
   PubMed Web of Science ®Google Scholar
• Phillips SM, Banerjea A, Feakins R, Li SR, Bustin SA, Dorudi S. Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. Br J Surg 2004; 91:469 - 75; http://dx.doi.org/10.1002/bjs.4472; PMID: 15048750
   PubMed Web of Science ®Google Scholar
• Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28:3219 - 26; http://dx.doi.org/10.1200/JCO.2009.27.1825; PMID: 20498393
   PubMed Web of Science ®Google Scholar
• Linnebacher M, Gebert J, Rudy W, Woerner S, Yuan YP, Bork P, von Knebel Doeberitz M. Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int J Cancer 2001; 93:6 - 11; http://dx.doi.org/10.1002/ijc.1298; PMID: 11391614
   PubMed Web of Science ®Google Scholar
• Schwitalle Y, Kloor M, Eiermann S, Linnebacher M, Kienle P, Knaebel HP, Tariverdian M, Benner A, von Knebel Doeberitz M. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 2008; 134:988 - 97; http://dx.doi.org/10.1053/j.gastro.2008.01.015; PMID: 18395080
   PubMed Web of Science ®Google Scholar
• Saeterdal I, Bjørheim J, Lislerud K, Gjertsen MK, Bukholm IK, Olsen OC, Nesland JM, Eriksen JA, Møller M, Lindblom A, et al. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A 2001; 98:13255 - 60; http://dx.doi.org/10.1073/pnas.231326898; PMID: 11687624
   PubMed Web of Science ®Google Scholar
• Lazennec G, Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 2010; 16:133 - 44; http://dx.doi.org/10.1016/j.molmed.2010.01.003; PMID: 20163989
   PubMed Web of Science ®Google Scholar
• Ali S, Lazennec G. Chemokines: novel targets for breast cancer metastasis. Cancer Metastasis Rev 2007; 26:401 - 20; http://dx.doi.org/10.1007/s10555-007-9073-z; PMID: 17717637
   PubMed Web of Science ®Google Scholar
• Vindrieux D, Escobar P, Lazennec G. Emerging roles of chemokines in prostate cancer. Endocr Relat Cancer 2009; 16:663 - 73; http://dx.doi.org/10.1677/ERC-09-0109; PMID: 19556286
   PubMed Web of Science ®Google Scholar
• Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30:1073 - 81; http://dx.doi.org/10.1093/carcin/bgp127; PMID: 19468060
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454:436 - 44; http://dx.doi.org/10.1038/nature07205; PMID: 18650914
   PubMed Web of Science ®Google Scholar
• Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP, Belperio JA. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 2006; 42:768 - 78; http://dx.doi.org/10.1016/j.ejca.2006.01.006; PMID: 16510280
   PubMed Web of Science ®Google Scholar
• Mehrad B, Keane MP, Strieter RM. Chemokines as mediators of angiogenesis. Thromb Haemost 2007; 97:755 - 62; PMID: 17479186
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860 - 7; http://dx.doi.org/10.1038/nature01322; PMID: 12490959
   PubMed Web of Science ®Google Scholar
• Zlotnik A, Burkhardt AM, Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol 2011; 11:597 - 606; http://dx.doi.org/10.1038/nri3049; PMID: 21866172
   PubMed Web of Science ®Google Scholar
• Allen M, Louise Jones J. Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol 2011; 223:162 - 76; http://dx.doi.org/10.1002/path.2803; PMID: 21125673
   PubMed Web of Science ®Google Scholar
• Le Gouvello S, Bastuji-Garin S, Aloulou N, Mansour H, Chaumette MT, Berrehar F, Seikour A, Charachon A, Karoui M, Leroy K, et al. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 2008; 57:772 - 9; http://dx.doi.org/10.1136/gut.2007.123794; PMID: 17965063
   PubMed Web of Science ®Google Scholar
• Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pagès F, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011; 71:1263 - 71; http://dx.doi.org/10.1158/0008-5472.CAN-10-2907; PMID: 21303976
   PubMed Web of Science ®Google Scholar
• Oladipo O, Conlon S, O’Grady A, Purcell C, Wilson C, Maxwell PJ, Johnston PG, Stevenson M, Kay EW, Wilson RH, et al. The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue. Br J Cancer 2011; 104:480 - 7; http://dx.doi.org/10.1038/sj.bjc.6606055; PMID: 21285972
   PubMed Web of Science ®Google Scholar
• Halama N, Braun M, Kahlert C, Spille A, Quack C, Rahbari N, Koch M, Weitz J, Kloor M, Zoernig I, et al. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res 2011; 17:678 - 89; http://dx.doi.org/10.1158/1078-0432.CCR-10-2173; PMID: 21325295
   PubMed Web of Science ®Google Scholar
• Pagès F, Galon J, Fridman WH. The essential role of the in situ immune reaction in human colorectal cancer. J Leukoc Biol 2008; 84:981 - 7; http://dx.doi.org/10.1189/jlb.1107773; PMID: 18559950
   PubMed Web of Science ®Google Scholar
• Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, Giovannucci E, Dranoff G, Fuchs CS, Ogino S. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 2010; 222:350 - 66; http://dx.doi.org/10.1002/path.2774; PMID: 20927778
   PubMed Web of Science ®Google Scholar
• Guidoboni M, Gafà R, Viel A, Doglioni C, Russo A, Santini A, Del Tin L, Macrì E, Lanza G, Boiocchi M, et al. Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol 2001; 159:297 - 304; http://dx.doi.org/10.1016/S0002-9440(10)61695-1; PMID: 11438476
   PubMed Web of Science ®Google Scholar
• Laghi L, Bianchi P, Miranda E, Balladore E, Pacetti V, Grizzi F, Allavena P, Torri V, Repici A, Santoro A, et al. CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol 2009; 10:877 - 84; http://dx.doi.org/10.1016/S1470-2045(09)70186-X; PMID: 19656725
   PubMed Web of Science ®Google Scholar
• Michel S, Benner A, Tariverdian M, Wentzensen N, Hoefler P, Pommerencke T, Grabe N, von Knebel Doeberitz M, Kloor M. High density of FOXP3-positive T cells infiltrating colorectal cancers with microsatellite instability. Br J Cancer 2008; 99:1867 - 73; http://dx.doi.org/10.1038/sj.bjc.6604756; PMID: 18985040
   PubMed Web of Science ®Google Scholar
• Prall F, Dührkop T, Weirich V, Ostwald C, Lenz P, Nizze H, Barten M. Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol 2004; 35:808 - 16; http://dx.doi.org/10.1016/j.humpath.2004.01.022; PMID: 15257543
   PubMed Web of Science ®Google Scholar
• Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta B. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009; 27:186 - 92; http://dx.doi.org/10.1200/JCO.2008.18.7229; PMID: 19064967
   PubMed Web of Science ®Google Scholar
• Mullen AC, High FA, Hutchins AS, Lee HW, Villarino AV, Livingston DM, Kung AL, Cereb N, Yao TP, Yang SY, et al. Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science 2001; 292:1907 - 10; http://dx.doi.org/10.1126/science.1059835; PMID: 11397944
   PubMed Web of Science ®Google Scholar
• Frey DM, Droeser RA, Viehl CT, Zlobec I, Lugli A, Zingg U, Oertli D, Kettelhack C, Terracciano L, Tornillo L. High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer 2010; 126:2635 - 43; PMID: 19856313
   PubMed Web of Science ®Google Scholar
• Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009; 27:5944 - 51; http://dx.doi.org/10.1200/JCO.2008.19.6147; PMID: 19858404
   PubMed Web of Science ®Google Scholar
• Suzuki H, Chikazawa N, Tasaka T, Wada J, Yamasaki A, Kitaura Y, Sozaki M, Tanaka M, Onishi H, Morisaki T, et al. Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer. Cancer Immunol Immunother 2010; 59:653 - 61; http://dx.doi.org/10.1007/s00262-009-0781-9; PMID: 19908042
   PubMed Web of Science ®Google Scholar
• Correale P, Rotundo MS, Del Vecchio MT, Remondo C, Migali C, Ginanneschi C, Tsang KY, Licchetta A, Mannucci S, Loiacono L, et al. Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother 2010; 33:435 - 41; http://dx.doi.org/10.1097/CJI.0b013e3181d32f01; PMID: 20386463
   PubMed Web of Science ®Google Scholar
• Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007; 117:1167 - 74; http://dx.doi.org/10.1172/JCI31202; PMID: 17476346
   PubMed Web of Science ®Google Scholar
• Chaput N, Louafi S, Bardier A, Charlotte F, Vaillant JC, Ménégaux F, Rosenzwajg M, Lemoine F, Klatzmann D, Taieb J. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut 2009; 58:520 - 9; http://dx.doi.org/10.1136/gut.2008.158824; PMID: 19022917
   PubMed Web of Science ®Google Scholar
• Blatner NR, Bonertz A, Beckhove P, Cheon EC, Krantz SB, Strouch M, Weitz J, Koch M, Halverson AL, Bentrem DJ, et al. In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proc Natl Acad Sci U S A 2010; 107:6430 - 5; http://dx.doi.org/10.1073/pnas.0913683107; PMID: 20308560
   PubMed Web of Science ®Google Scholar
• deLeeuw RJ, Kost SE, Kakal JA, Nelson BH. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 2012; 18:3022 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-11-3216; PMID: 22510350
   PubMed Web of Science ®Google Scholar
• Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, Sargent DJ. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 2009; 137:1270 - 9; http://dx.doi.org/10.1053/j.gastro.2009.06.053; PMID: 19577568
   PubMed Web of Science ®Google Scholar
• Lee WS, Park S, Lee WY, Yun SH, Chun HK. Clinical impact of tumor-infiltrating lymphocytes for survival in stage II colon cancer. Cancer 2010; 116:5188 - 99; http://dx.doi.org/10.1002/cncr.25293; PMID: 20665489
   PubMed Web of Science ®Google Scholar
• Tougeron D, Fauquembergue E, Rouquette A, Le Pessot F, Sesboüé R, Laurent M, Berthet P, Mauillon J, Di Fiore F, Sabourin JC, et al. Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations. Mod Pathol 2009; 22:1186 - 95; http://dx.doi.org/10.1038/modpathol.2009.80; PMID: 19503063
   PubMed Web of Science ®Google Scholar
• Rubie C, Frick VO, Wagner M, Schuld J, Gräber S, Brittner B, Bohle RM, Schilling MK. ELR+ CXC chemokine expression in benign and malignant colorectal conditions. BMC Cancer 2008; 8:178; http://dx.doi.org/10.1186/1471-2407-8-178; PMID: 18578857
   PubMed Web of Science ®Google Scholar
• Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q, Richmond A, Strieter R, Dey SK, DuBois RN. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med 2006; 203:941 - 51; http://dx.doi.org/10.1084/jem.20052124; PMID: 16567391
   PubMed Web of Science ®Google Scholar
• Jiang Z, Xu Y, Cai S. CXCL10 expression and prognostic significance in stage II and III colorectal cancer. Mol Biol Rep 2010; 37:3029 - 36; http://dx.doi.org/10.1007/s11033-009-9873-z; PMID: 19821051
   PubMed Web of Science ®Google Scholar
• Musha H, Ohtani H, Mizoi T, Kinouchi M, Nakayama T, Shiiba K, Miyagawa K, Nagura H, Yoshie O, Sasaki I. Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma. Int J Cancer 2005; 116:949 - 56; http://dx.doi.org/10.1002/ijc.21135; PMID: 15856455
   PubMed Web of Science ®Google Scholar
• Brew R, Southern SA, Flanagan BF, McDicken IW, Christmas SE. Detection of interleukin-8 mRNA and protein in human colorectal carcinoma cells. Eur J Cancer 1996; 32A:2142 - 7; http://dx.doi.org/10.1016/S0959-8049(96)00221-3; PMID: 9014758
   PubMed Web of Science ®Google Scholar
• Cui G, Yuan A, Goll R, Vonen B, Florholmen J. Dynamic changes of interleukin-8 network along the colorectal adenoma-carcinoma sequence. Cancer Immunol Immunother 2009; 58:1897 - 905; http://dx.doi.org/10.1007/s00262-009-0702-y; PMID: 19350238
   PubMed Web of Science ®Google Scholar
• Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 2011; 11:519 - 31; http://dx.doi.org/10.1038/nri3024; PMID: 21785456
   PubMed Web of Science ®Google Scholar
• Galdiero MR, Garlanda C, Jaillon S, Marone G, Mantovani A. Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol 2013; 228:1404 - 12; http://dx.doi.org/10.1002/jcp.24260; PMID: 23065796
   PubMed Web of Science ®Google Scholar
• Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004; 4:540 - 50; http://dx.doi.org/10.1038/nrc1388; PMID: 15229479
   PubMed Web of Science ®Google Scholar
• Homey B, Müller A, Zlotnik A. Chemokines: agents for the immunotherapy of cancer?. Nat Rev Immunol 2002; 2:175 - 84; http://dx.doi.org/10.1038/nri748; PMID: 11913068
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Schwenk U, Maune S, Bartels J, Küpper M, Fichtner I, Schröder JM, Schadendorf D. The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br J Cancer 1999; 79:1025 - 31; http://dx.doi.org/10.1038/sj.bjc.6690164; PMID: 10098731
   PubMed Web of Science ®Google Scholar
• Sugasawa H, Ichikura T, Kinoshita M, Ono S, Majima T, Tsujimoto H, Chochi K, Hiroi S, Takayama E, Saitoh D, et al. Gastric cancer cells exploit CD4+ cell-derived CCL5 for their growth and prevention of CD8+ cell-involved tumor elimination. Int J Cancer 2008; 122:2535 - 41; http://dx.doi.org/10.1002/ijc.23401; PMID: 18246596
   PubMed Web of Science ®Google Scholar
• Soria G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 2008; 267:271 - 85; http://dx.doi.org/10.1016/j.canlet.2008.03.018; PMID: 18439751
   PubMed Web of Science ®Google Scholar
• Cambien B, Richard-Fiardo P, Karimdjee BF, Martini V, Ferrua B, Pitard B, Schmid-Antomarchi H, Schmid-Alliana A. CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRβ in colorectal carcinoma. PLoS One 2011; 6:e28842; http://dx.doi.org/10.1371/journal.pone.0028842; PMID: 22205974
   PubMed Web of Science ®Google Scholar
• Chang LY, Lin YC, Mahalingam J, Huang CT, Chen TW, Kang CW, Peng HM, Chu YY, Chiang JM, Dutta A, et al. Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res 2012; 72:1092 - 102; http://dx.doi.org/10.1158/0008-5472.CAN-11-2493; PMID: 22282655
   PubMed Web of Science ®Google Scholar
• Ning Y, Manegold PC, Hong YK, Zhang W, Pohl A, Lurje G, Winder T, Yang D, LaBonte MJ, Wilson PM, et al. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer 2011; 128:2038 - 49; http://dx.doi.org/10.1002/ijc.25562; PMID: 20648559
   PubMed Web of Science ®Google Scholar
• Banerjea A, Ahmed S, Hands RE, Huang F, Han X, Shaw PM, Feakins R, Bustin SA, Dorudi S. Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity. Mol Cancer 2004; 3:21; http://dx.doi.org/10.1186/1476-4598-3-21; PMID: 15298707
   PubMed Web of Science ®Google Scholar
• Strieter RM, Polverini PJ, Arenberg DA, Kunkel SL. The role of CXC chemokines as regulators of angiogenesis. Shock 1995; 4:155 - 60; http://dx.doi.org/10.1097/00024382-199509000-00001; PMID: 8574748
   PubMed Web of Science ®Google Scholar
• Padovan E, Spagnoli GC, Ferrantini M, Heberer M. IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. J Leukoc Biol 2002; 71:669 - 76; PMID: 11927654
   PubMed Web of Science ®Google Scholar
• Kim HJ, Song DE, Lim SY, Lee SH, Kang JL, Lee SJ, Benveniste EN, Choi YH. Loss of the promyelocytic leukemia protein in gastric cancer: implications for IP-10 expression and tumor-infiltrating lymphocytes. PLoS One 2011; 6:e26264; http://dx.doi.org/10.1371/journal.pone.0026264; PMID: 22022583
   PubMed Web of Science ®Google Scholar
• Bandapalli OR, Ehrmann F, Ehemann V, Gaida M, Macher-Goeppinger S, Wente M, Schirmacher P, Brand K. Down-regulation of CXCL1 inhibits tumor growth in colorectal liver metastasis. Cytokine 2012; 57:46 - 53; http://dx.doi.org/10.1016/j.cyto.2011.10.019; PMID: 22129625
   PubMed Web of Science ®Google Scholar
• Chiu ST, Hsieh FJ, Chen SW, Chen CL, Shu HF, Li H. Clinicopathologic correlation of up-regulated genes identified using cDNA microarray and real-time reverse transcription-PCR in human colorectal cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:437 - 43; http://dx.doi.org/10.1158/1055-9965.EPI-04-0396; PMID: 15734970
   PubMed Web of Science ®Google Scholar
• Jass JR, Atkin WS, Cuzick J, Bussey HJ, Morson BC, Northover JM, Todd IP. The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology 1986; 10:437 - 59; http://dx.doi.org/10.1111/j.1365-2559.1986.tb02497.x; PMID: 3721406
   PubMed Web of Science ®Google Scholar
• Boissière-Michot F, Denouël A, Boulle N, Guillaume C, Orsetti B, Lopez-Crapez E, Chateau MC, Bibeau F. The non-crosslinking fixative RCL2®-CS100 is compatible with both pathology diagnosis and molecular analyses. Pathol Oncol Res 2013; 19:41 - 53; http://dx.doi.org/10.1007/s12253-012-9556-2; PMID: 22893391
   PubMed Web of Science ®Google Scholar
• Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissière F, Laune D, Roques S, Lazennec G. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 2007; 9:R15; http://dx.doi.org/10.1186/bcr1648; PMID: 17261184
   PubMed Web of Science ®Google Scholar